Form 4: Regulus Therapeutics CEO Disposes All Equity Following Novartis Acquisition Completion

Joseph P. Hagan, CEO and Director of Regulus Therapeutics Inc., has disposed of all his beneficial ownership in the company following its acquisition by Novartis AG, converting shares, options, PSUs, and warrants into cash and contingent value rights.

Summary

• Regulus Therapeutics Inc. (RGLS) has been acquired by Novartis AG, with the merger becoming effective on June 25, 2025.
• Joseph P. Hagan, the Chief Executive Officer and Director, disposed of all his common stock, stock options, performance stock units (PSUs), and warrants in Regulus Therapeutics Inc. as a result of the merger.
• Each share of Regulus common stock was converted into the right to receive $7.00 in cash (the 'Closing Amount') plus one contingent value right (CVR).
• Each CVR represents the right to receive an additional $7.00 in cash upon the achievement of a specified milestone, bringing the potential total value per share to $14.00.
• Performance Stock Units (PSUs) held by Mr. Hagan, totaling 280,750, were canceled and converted into cash equal to the product of the underlying shares and the Closing Amount, plus one CVR per underlying share.
• In-the-Money Stock Options (exercise price less than $7.00) were canceled and converted into cash equal to the difference between the Closing Amount and the exercise price, multiplied by the number of underlying shares, plus one CVR per underlying share.
• Out-of-the-Money Stock Options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with a potential future cash payment if the milestone is met.
• Common Stock Purchase Warrants, totaling 2,976, were converted into a cash payment of $2.95 per warrant, based on their Black Scholes Value.
• Following these transactions, Joseph P. Hagan holds 0 shares and 0 derivative securities in Regulus Therapeutics Inc.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the merger successfully completed, providing shareholders with a defined cash value and potential upside via CVRs. The disposition of all insider equity is a natural consequence of the acquisition. The minor negative is the past reporting omission of PSUs, but it does not impact the merger's outcome.

Positives

• The merger provides Regulus Therapeutics shareholders with a defined cash value of $7.00 per share upfront.
• Shareholders also receive a Contingent Value Right (CVR) that offers potential for an additional $7.00 per share upon milestone achievement, providing upside potential.
• The acquisition by Novartis AG, a major pharmaceutical company, indicates a successful strategic outcome for Regulus Therapeutics.

Negatives

• The full potential value of $14.00 per share is contingent on a milestone being met, meaning the additional $7.00 from the CVR is not guaranteed.
• The filing notes that 280,750 PSUs were 'unintentionally omitted from previous Form 4 filings' by the Reporting Person, indicating a past reporting oversight.

Risks

• The primary risk is that the contingent payment of $7.00 per CVR will not be made if the specified milestone is not achieved, meaning shareholders would only receive the initial $7.00 cash payment.

Future Outlook

Following the merger, Regulus Therapeutics Inc. is now a wholly owned subsidiary of Novartis AG. The future outlook for the former public entity is now integrated into Novartis's strategic plans. The primary forward-looking aspect for former shareholders is the potential for the contingent value right (CVR) payment of $7.00, which is dependent on the achievement of a specific milestone.

Industry Context

This filing reflects a significant event in the biotechnology sector, specifically a strategic acquisition by a major pharmaceutical company, Novartis AG. Such mergers and acquisitions are common in the biotech industry as larger companies seek to expand their pipelines and intellectual property through the acquisition of smaller, innovative firms. The use of Contingent Value Rights (CVRs) is also a common mechanism in biotech M&A to bridge valuation gaps and share future development risks or rewards.

Comparison to Industry Standards

• The document details a specific acquisition transaction and the disposition of insider equity, rather than ongoing operational results. Therefore, a direct comparison to industry standards for financial performance metrics (e.g., revenue, profit margins) is not applicable.
• While the acquisition price and CVR structure could be compared to other biotech M&A deals, the document does not provide sufficient context or details on comparable transactions, projects, or results to facilitate a specific, detailed assessment against global benchmarks for acquisition valuations.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and contingent value rights for their shares, concluding their investment in the public entity.
• Employees (including management): Equity holdings were converted into cash and CVRs as part of the acquisition terms.
• Company (Regulus Therapeutics Inc.): Transformed from a publicly traded entity into a private, wholly-owned subsidiary of Novartis AG.

Next Steps

• Achievement and payment of the contingent value right (CVR) based on the specified milestone.

Key Dates

Keywords

Regulus Therapeutics, RGLS, Novartis AG, Merger, Acquisition, SEC Form 4, Insider Transaction, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Performance Stock Units, PSUs, Warrants